The headline trial: No GLP-1 RCT enrolled lactating women
GLP-1 receptor agonists were not studied during lactation in registration trials. FDA labeling for semaglutide and tirzepatide notes lactation data is insufficient and the drug should be avoided during breastfeeding.
FDA prescribing information for Wegovy, Ozempic, Zepbound, Mounjaro (current 2026 labels)
There is no published RCT or pharmacokinetic study of GLP-1 RA in lactating women. Animal studies showed GLP-1 RA exposure in milk. FDA labels for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) recommend against use during breastfeeding due to insufficient safety data. The conservative clinical recommendation across endocrine and obesity-medicine societies is to defer GLP-1 RA until breastfeeding is completed.
Trial enrollment criteria
- Not applicable, GLP-1 RA is not recommended in this clinical context
Does this trial apply to you?
Defer GLP-1 RA until breastfeeding is fully completed. If a patient wishes to start GLP-1 RA while breastfeeding, the safest path is to wait until weaning is complete (typically 6 to 12 months postpartum, sometimes longer). Postpartum weight retention is a real clinical concern, but the evidence base does not support starting GLP-1 RA during lactation in 2026.
What to ask your prescriber
- Realistic timeline to weaning or transition to combination feeding
- Whether structured postpartum nutrition counseling can bridge the period before GLP-1 RA initiation
- Whether other non-GLP-1 anti-obesity options (phentermine, orlistat, naltrexone-bupropion) are compatible with lactation
- Monitoring of postpartum cardiometabolic risk in the interim
Editorial notes
- Postpartum weight retention is not a failure of self-discipline; it is a recognized clinical entity with hormonal and lifestyle drivers. Defer is not the same as ignore.
- If you stop breastfeeding before 6 months, recheck FDA labeling and prescribing-information updates, the evidence base may have shifted.
- Postpartum depression and anxiety can affect weight; coordinate care with your OB/GYN before adding pharmacotherapy of any kind.
Clinical trials for Breastfeeding and postpartum
Or browse the full GLP-1 clinical trials directory, filterable by condition, state and phase.
Drug profiles
Other GLP-1 conditions
Editorial provenance
Editorial review by John, Editor on 2026-05-23, against No GLP-1 RCT enrolled lactating women (FDA prescribing information for Wegovy, Ozempic, Zepbound, Mounjaro (current 2026 labels)). We do not yet have a credentialed medical reviewer on staff (actively recruiting). This page summarises public registration-trial data and FDA labeling. It is not clinician-authored medical advice.
Disclaimer
Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.